At Chiesi Diversity & Inclusion (D&I) is part of our culture: as a Benefit company and a certified B Corp, we aim to further enhance an inclusive and open approach in our daily actions, ensuring the well-being of our people, openness to others, a sense of welcome and thus improving individual and team performance.
Ethnicity, sexual orientation, gender identity, socioeconomic status, age, physical abilities, religion, political views, lifestyle, and other invisible diversities represent the set of personal characteristics that make each individual unique. In Chiesi we want to give value to all these differences, so that everyone can express the best of themselves.
With this in mind, Chiesi is reinforcing its commitment to this approach through the Global D&I Policy, a document adopted by the entire Group, which aims to explain the values and behaviours that the Company promotes and adopts in order to create an inclusive environment. The policy is indeed encouraging a culture based on the acceptance and the inclusiveness, the respect for all the differences, the creation of development opportunities for all our people based on their merit and their talents, the promotion of an inclusive leadership.
Because Everyone of us is different, everyone of us is Chiesi.
About Chiesi Group
Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. In 2018 Chiesi has changed its legal status to a Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.